Else Nutrition CEO Highlights Urgent Need for Infant Formula Alternatives in The Washington Times Op-Ed

In This Article:

VANCOUVER, BC, May 28, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in wholefood, Plant-Based nutrition for babies, toddlers, children and adults, is pleased to announce that its CEO and Co-Founder, Hamutal Yitzhak, authored a featured op-ed published in The Washington Times on May 25, 2025. Titled "Operation Stork Speed will ensure babies get the nutrition they need," the piece highlights the urgent need to modernize the infant formula regulatory environment and emphasizes the importance of increasing access to safe and innovative nutrition options—particularly for infants with dietary restrictions or allergen sensitivities. The Washington Times has a substantial readership in Washington, D.C., particularly among Congress and the Administration.

Else Nutrition Holdings Inc. logo (CNW Group/Else Nutrition Holdings Inc.)
Else Nutrition Holdings Inc. logo (CNW Group/Else Nutrition Holdings Inc.)

"Our mission has always been to deliver a safe, plant-based infant formula that supports healthy development and gives families—especially those with dietary or dairy/soy allergen concerns—greater access to trusted nutrition," said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "Operation Stork Speed is an excellent initiative designed to expand access to these types of formulas, and as noted in the Washington Times op-ed, we look forward to continuing to collaborate with the White House, policymakers, and the FDA as we look to bring our unique solution to market in a swift and responsible manner."

Regulatory Pathway and Status

Else Nutrition has developed a clean-label, whole plant-based infant formula intended as an alternative to dairy- and soy-based products. In 2023, the Company successfully concluded the pre-clinical studies required and received Institutional Review Board (IRB) approval for its infant growth clinical study protocol—marking a key step toward U.S. Food and Drug Administration (FDA) compliance. At present, the Company is awaiting final authorization from the FDA to initiate its clinical trial in the United States, pending regulatory modernization that the company believes may be accelerated through Operation Stork Speed. Several Congressional Appropriators recently called on the FDA to accelerate this effort, as directed through an oversight letter.

Policy Advocacy and Operation Stork Speed

The op-ed coincides with the recent launch of Operation Stork Speed, an initiative by the Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr., aimed at improving the regulatory review and safety of infant formula in the United States as well as encouraging innovation and transparency in formula composition to serve unmet needs. Ms. Yitzhak's commentary lends industry perspective to this national conversation and urges regulatory authorities to accelerate the path to market for scientifically supported, non-traditional formula options.